StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Phase IIb initiation and multi-site expansion represent a tangible development catalyst; positive data could improve regulatory prospects and drive upside, though outcome risk remains high given early-stage nature.
What happened, with direct paths to the underlying reporting
SciSparc’s NeuroThera Labs initiated a Phase IIb site at Hannover Medical School for SCI-110 in adults with Tourette Syndrome, with Yale and Tel Aviv centers following. Building on Phase IIa’s 21% tic reduction, the randomized, double-blind, placebo-controlled cross-over study aims to further assess efficacy and safety, potentially informing a regulatory pathway if results are favorable.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.